Centonze Giovanni, Biganzoli Davide, Prinzi Natalie, Pusceddu Sara, Mangogna Alessandro, Tamborini Elena, Perrone Federica, Busico Adele, Lagano Vincenzo, Cattaneo Laura, Sozzi Gabriella, Roz Luca, Biganzoli Elia, Milione Massimo
1st Pathology Division, Department of Pathology and Laboratory Medicine, Fondazione IRCCS (Scientific Institute for Research, Hospitalization and Healthcare) Istituto Nazionale dei Tumori, via Venezian 1, 20133 Milan, Italy.
Tumor Genomics Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, via Venezian 1, 20133 Milan, Italy.
Cancers (Basel). 2020 Sep 24;12(10):2753. doi: 10.3390/cancers12102753.
Lung neuroendocrine neoplasms (LNENs) represent a rare and heterogeneous population of lung tumors. LNENs incidence rate has increased dramatically over the past 30 years. The current World Health Organization LNENs classification (WHO 2015), distinguished four LNENs prognostic categories, according to their morphology, necrosis amount and mitotic count: typical carcinoid (TC), atypical-carcinoid (AC), large cell neuroendocrine carcinoma (LCNEC) and small cell lung cancer (SCLC). At present, due to their rarity and biological heterogeneity there is still no consensus on the best therapeutic approach. Next-generation-sequencing analysis showed that WHO 2015 LNENs classes, could be characterized also by specific molecular alterations: frequently mutated genes involving chromatin remodeling and generally characterized by low mutational burden (MB) are frequently detected in both TC and AC; otherwise, and tumor suppressor genes alterations and high MB are usually detected in LCNEC and SCLC. We provide an overview concerning gene mutations in each WHO 2015 LNENs class in order to report the current LNENs mutational status as potential tool to better understand their clinical outcome and to drive medical treatment.
肺神经内分泌肿瘤(LNENs)是一类罕见且异质性的肺肿瘤。在过去30年中,LNENs的发病率急剧上升。根据其形态、坏死量和有丝分裂计数,目前世界卫生组织的LNENs分类(2015年WHO)区分了四种LNENs预后类别:典型类癌(TC)、非典型类癌(AC)、大细胞神经内分泌癌(LCNEC)和小细胞肺癌(SCLC)。目前,由于其罕见性和生物学异质性,对于最佳治疗方法仍未达成共识。下一代测序分析表明,2015年WHO的LNENs类别也可通过特定的分子改变来表征:在TC和AC中经常检测到涉及染色质重塑且通常具有低突变负荷(MB)的频繁突变基因;否则,在LCNEC和SCLC中通常检测到肿瘤抑制基因改变和高MB。我们提供了关于2015年WHO各LNENs类别中基因突变的概述,以便报告当前LNENs的突变状态,作为更好地了解其临床结果和指导医疗治疗的潜在工具。